NASDAQ:SRPT Sarepta Therapeutics (SRPT) Stock Price, News & Analysis $144.24 -3.32 (-2.25%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$143.31▼$148.1250-Day Range$113.33▼$163.8552-Week Range$55.25▼$173.25Volume964,277 shsAverage Volume1.38 million shsMarket Capitalization$13.63 billionP/E Ratio1,311.27Dividend YieldN/APrice Target$187.72 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Sarepta Therapeutics alerts: Email Address Sarepta Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.78 Rating ScoreUpside/Downside30.1% Upside$187.72 Price TargetShort InterestHealthy7.75% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment0.82Based on 11 Articles This WeekInsider TradingSelling Shares$8.09 M Sold Last QuarterProj. Earnings Growth146.01%From $3.76 to $9.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.91 out of 5 starsMedical Sector23rd out of 936 stocksPharmaceutical Preparations Industry5th out of 436 stocks 4.4 Analyst's Opinion Consensus RatingSarepta Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 14 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSarepta Therapeutics has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Sarepta Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.75% of the outstanding shares of Sarepta Therapeutics have been sold short.Short Interest Ratio / Days to CoverSarepta Therapeutics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sarepta Therapeutics has recently decreased by 23.33%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSarepta Therapeutics does not currently pay a dividend.Dividend GrowthSarepta Therapeutics does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSarepta Therapeutics has received a 62.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication", "Clinical research services", and "Preclinical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Sarepta Therapeutics is -1.65. Previous Next 2.7 News and Social Media Coverage News SentimentSarepta Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 21 people have searched for SRPT on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.MarketBeat FollowsOnly 13 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,086,386.00 in company stock.Percentage Held by InsidersOnly 7.70% of the stock of Sarepta Therapeutics is held by insiders.Percentage Held by Institutions86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sarepta Therapeutics' insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Sarepta Therapeutics are expected to grow by 146.01% in the coming year, from $3.76 to $9.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sarepta Therapeutics is 1,311.27, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 143.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Sarepta Therapeutics is 1,311.27, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 164.48.Price to Book Value per Share RatioSarepta Therapeutics has a P/B Ratio of 15.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Sarepta Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Sarepta Therapeutics Stock (NASDAQ:SRPT)Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.Read More SRPT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SRPT Stock News HeadlinesJune 26, 2024 | insidertrades.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Sells $1,281,645.72 in StockJuly 24 at 6:08 PM | seekingalpha.comSarepta Therapeutics' Pullback After Recent FDA Approval A Buying OpportunityJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | theglobeandmail.comBiotech ETF (XBI) Rallied from the Blue Box Hitting TargetJuly 21, 2024 | msn.com'Contagion': This market expert warns that America's real estate problem may not be limited to commercial properties — here are 3 'idiosyncratic' stocks he likesJuly 21, 2024 | finance.yahoo.comThis market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likesJuly 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Sarepta Therapeutics Amid Strong Elevidys Demand and Strategic Growth OutlookJuly 19, 2024 | benzinga.comHere's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth TodayJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 6, 2024 | fool.comAfter a Big Win, Is Sarepta Therapeutics Stock a Buy?July 4, 2024 | fool.comHas Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News?July 3, 2024 | fool.com1 Soaring Growth Stock to Buy and Hold for 10 YearsJune 26, 2024 | fool.comIs Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It.June 26, 2024 | gurufocus.comInsider Sale: EVP, General Counsel Ryan Brown Sells 38,957 Shares of Sarepta Therapeutics Inc (SRPT)June 22, 2024 | seekingalpha.comSarepta Therapeutics: Pushing The Edge And Creating The HorizonJune 21, 2024 | seekingalpha.comSarepta Therapeutics: Why Today's Rally On DMD Drug Label Expansion Won't LastJune 21, 2024 | businesswire.comWall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label ApprovalJune 21, 2024 | benzinga.comSarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst SaysSee More Headlines Receive SRPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SRPT Previous SymbolNASDAQ:AVII CUSIPN/A CIK873303 Webwww.sareptatherapeutics.com Phone(617) 274-4000Fax425-354-5038Employees1,314Year Founded1980Price Target and Rating Average Stock Price Target$187.72 High Stock Price Target$235.00 Low Stock Price Target$109.00 Potential Upside/Downside+30.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio1,311.27 Forward P/E Ratio38.36 P/E GrowthN/ANet Income$-535,980,000.00 Net Margins1.20% Pretax Margin2.43% Return on Equity2.20% Return on Assets0.58% Debt Debt-to-Equity Ratio1.18 Current Ratio4.05 Quick Ratio3.44 Sales & Book Value Annual Sales$1.24 billion Price / Sales10.97 Cash FlowN/A Price / Cash FlowN/A Book Value$9.19 per share Price / Book15.70Miscellaneous Outstanding Shares94,520,000Free Float87,246,000Market Cap$13.63 billion OptionableOptionable Beta0.89 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Douglas S. Ingram Esq. (Age 61)President, CEO & Director Comp: $1.62MMr. Ian Michael Estepan (Age 48)Executive VP & CFO Comp: $917.53kDr. Louise R. Rodino-Klapac Ph.D. (Age 46)Executive VP, Chief Scientific Officer and Head of Research & Development Comp: $1.04MMr. Ryan E. Brown J.D. (Age 46)Executive VP, General Counsel & Corporate Secretary Comp: $823.36kMr. Bilal Arif (Age 52)Executive VP & Chief Technical Operations Officer Ms. Francesca T. NolanExecutive Director of Investor Relations and Corporate CommunicationsMs. Alison NasisiExecutive VP & Chief People OfficerDr. Diane L. Berry Ph.D.Executive VP and Chief of Global Policy & Advocacy OfficerMr. Dallan MurrayExecutive VP & Chief Customer OfficerMr. Will TiltonSenior VP, Head of Strategy & Chief of StaffMore ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXACADIA PharmaceuticalsNASDAQ:ACADPTC TherapeuticsNASDAQ:PTCTWave Life SciencesNASDAQ:WVESolid BiosciencesNASDAQ:SLDBView All CompetitorsInsiders & InstitutionsEFG Asset Management North America Corp.Sold 2,221 shares on 7/26/2024Ownership: 0.028%State of Michigan Retirement SystemBought 22,800 shares on 7/26/2024Ownership: 0.024%Allspring Global Investments Holdings LLCSold 239,511 shares on 7/26/2024Ownership: 0.023%AlphaCentric Advisors LLCBought 7,231 shares on 7/26/2024Ownership: 0.008%Cambridge Investment Research Advisors Inc.Bought 120 shares on 7/26/2024Ownership: 0.007%View All Insider TransactionsView All Institutional Transactions SRPT Stock Analysis - Frequently Asked Questions How have SRPT shares performed this year? Sarepta Therapeutics' stock was trading at $96.43 at the beginning of the year. Since then, SRPT shares have increased by 49.6% and is now trading at $144.24. View the best growth stocks for 2024 here. How were Sarepta Therapeutics' earnings last quarter? Sarepta Therapeutics, Inc. (NASDAQ:SRPT) announced its quarterly earnings results on Wednesday, May, 1st. The biotechnology company reported $0.73 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.84. The business's revenue was up 63.1% compared to the same quarter last year. What is Douglas S. Ingram's approval rating as Sarepta Therapeutics' CEO? 15 employees have rated Sarepta Therapeutics Chief Executive Officer Douglas S. Ingram on Glassdoor.com. Douglas S. Ingram has an approval rating of 95% among the company's employees. This puts Douglas S. Ingram in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. Does Sarepta Therapeutics have any subsidiaries? Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc.. Who are Sarepta Therapeutics' major shareholders? Sarepta Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.38%), Retirement Systems of Alabama (0.12%), New York State Teachers Retirement System (0.08%) and Banque Pictet & Cie SA (0.04%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac. View institutional ownership trends. How do I buy shares of Sarepta Therapeutics? Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Sarepta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Alibaba Group (BABA) and Netflix (NFLX). This page (NASDAQ:SRPT) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
